Show simple item record

dc.contributor.authorKumar, Radhika
dc.contributor.authorDohlman, Claes Henrik
dc.contributor.authorChodosh, James
dc.date.accessioned2013-04-08T20:29:06Z
dc.date.issued2012
dc.identifier.citationKumar, Radhika, Claes H Dohlman, and James Chodosh. 2012. Oral acetazolamide after Boston keratoprosthesis in Stevens Johnson syndrome. BMC Research Notes 5: 205.en_US
dc.identifier.issn1756-0500en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10512594
dc.description.abstractBackground: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but severe and sometimes fatal condition associated with exposure to medications; sulfamethoxazole is among the most common causes. We sought to address the safety of acetazolamide, a chemically related compound, in patients with prior SJS/TEN and glaucoma. A retrospective case series is described of patients at the Massachusetts Eye and Ear Infirmary who underwent keratoprosthesis surgery for corneal blindness from SJS/TEN, and later required oral acetazolamide for elevated intraocular pressure. Findings: Over the last 10 years, 17 patients with SJS/TEN received a Boston keratoprosthesis. Of these, 11 developed elevated intraocular pressure that required administration of oral acetazolamide. One of 11 developed a mild allergic reaction, but no patient experienced a recurrence of SJS/TEN or any severe adverse reaction. Conclusion: Although an increase in the rate of recurrent SJS/TEN due to oral acetazolamide would not necessarily be apparent after treating only 11 patients, in our series, acetazolamide administration was well tolerated without serious sequela.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi:10.1186/1756-0500-5-205en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469385/pdf/en_US
dash.licenseLAA
dc.subjectStevens Johnson syndromeen_US
dc.subjectToxic epidermal necrolysisen_US
dc.subjectAcetazolamideen_US
dc.subjectGlaucomaen_US
dc.titleOral Acetazolamide after Boston Keratoprosthesis in Stevens Johnson Syndromeen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBMC Research Notesen_US
dash.depositing.authorDohlman, Claes Henrik
dc.date.available2013-04-08T20:29:06Z
dc.identifier.doi10.1186/1756-0500-5-205*
dash.contributor.affiliatedDohlman, Claes
dash.contributor.affiliatedChodosh, James


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record